WO2022203251A1 - 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 - Google Patents
사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 Download PDFInfo
- Publication number
- WO2022203251A1 WO2022203251A1 PCT/KR2022/003423 KR2022003423W WO2022203251A1 WO 2022203251 A1 WO2022203251 A1 WO 2022203251A1 KR 2022003423 W KR2022003423 W KR 2022003423W WO 2022203251 A1 WO2022203251 A1 WO 2022203251A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hearing loss
- extract
- preventing
- bilberry
- sapogrylate
- Prior art date
Links
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 38
- 206010011878 Deafness Diseases 0.000 title claims abstract description 37
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 37
- 230000010370 hearing loss Effects 0.000 title claims abstract description 37
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 48
- 244000078534 Vaccinium myrtillus Species 0.000 title abstract description 30
- 235000017537 Vaccinium myrtillus Nutrition 0.000 title abstract description 30
- 239000000284 extract Substances 0.000 title abstract description 25
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 title abstract 2
- 229950005789 sarpogrelate Drugs 0.000 title abstract 2
- 210000002768 hair cell Anatomy 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 235000019209 bilberry extract Nutrition 0.000 claims description 35
- 229940102480 bilberry extract Drugs 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 206010011903 Deafness traumatic Diseases 0.000 claims description 13
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 231100000199 ototoxic Toxicity 0.000 claims description 9
- 230000002970 ototoxic effect Effects 0.000 claims description 9
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 12
- 241000252212 Danio rerio Species 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 7
- 210000002266 hair cells auditory Anatomy 0.000 abstract description 4
- 230000030833 cell death Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 239000000401 methanolic extract Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003477 cochlea Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010063602 Exposure to noise Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001190 lateral line system Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000002985 organ of corti Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108010008359 protein kinase C lambda Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the present invention relates to a composition for preventing or treating hearing loss in a combination formulation containing sapogrylate and bilberry extract as active ingredients.
- Hearing loss or hearing loss is a common disease that about 15-20% of the population has, but it is a disease that greatly affects the quality of life. Recently, the number of people with hearing loss is increasing rapidly due to the aging population and the spread of digital devices, and since hearing impairment is permanent and difficult to treat fundamentally, it is very important to prevent it before it occurs.
- the ear is divided into the outer ear (from the pinna to the eardrum), the middle ear (from the eardrum to the cochlea), and the inner ear (the inside of the cochlea). Even with treatment, recovery is very difficult.
- Hearing loss can be divided into age-related hearing loss, pediatric hearing loss, Meniere's disease, sudden hearing loss, noise-induced hearing loss, and ototoxic hearing loss. Noise-induced hearing loss is increasing rapidly.
- Human hearing organs are affected by noises of 75 dBA or higher, and this level of noise is equivalent to living in a noise harmful to hearing organs in industrial society.
- the use of earphones often exposes the auditory organs to loud sounds, so noise-induced hearing loss patients are increasing in various age groups. Noise-induced hearing loss at a young age is progressively more severe with age and affects people at various ages.
- ototoxic hearing loss is caused by apoptosis of free radicals produced by ototoxic drugs.
- An object of the present invention is to provide a pharmaceutical composition and health food for preventing or treating hearing loss caused by reactive oxygen species caused by noise or drug exposure by using a composition containing sapogrylate and bilberry extract as active ingredients.
- the present invention provides a pharmaceutical composition for preventing or treating hearing loss containing sapogrylate and bilberry extract as active ingredients.
- the present invention provides a health food for preventing or improving hearing loss containing sapogrylate and bilberry extract as active ingredients.
- a composition containing as an active ingredient a complex composition in which sapogrylate and bilberry extract are mixed in a weight ratio of 1: (0.125-8) is a hair cell caused by reactive oxygen species generated by hydrogen peroxide in a small dose.
- a composition containing the sapogrylate and bilberry extract as an active ingredient can be provided as a composition for preventing or treating sensorineural hearing loss have.
- Figure 2 is the result of confirming the efficacy test on hair cells in the zebrafish efficacy model of the composite composition according to the composition ratio of the present invention.
- 3 is a result of a comparative test on the effect of hearing improvement in an in vivo noise-induced hearing loss mouse model of sapogrylate, bilberry extract, and the complex composition of the present invention.
- Noise and ototoxic drugs generate reactive oxygen species, and the produced active oxygen induces apoptosis of auditory cells, resulting in noise-induced hearing loss and ototoxic hearing loss. While researching a therapeutic agent to more effectively treat Accordingly, the present invention was completed.
- the present invention may provide a pharmaceutical composition for preventing or treating hearing loss containing sapogrylate and bilberry extract as active ingredients.
- the hearing loss may be selected from the group consisting of noise-induced hearing loss, ototoxic hearing loss, age-related hearing loss, and sudden hearing loss.
- the hearing loss is noise-induced hearing loss induced by hydrogen peroxide or reactive oxygen species (ROS). or ototoxic hearing loss.
- ROS reactive oxygen species
- the pharmaceutical composition may be a complex composition consisting of sapogrylate and bilberry extract 1: (0.125-8) by weight.
- the weight ratio of sapogrylate and bilberry extract is a composite composition having a ratio of 1:2 to 4, and more preferably, the weight ratio of sapogrylate and bilberry extract is 1:3. .
- the composite composition may exhibit an enhanced hearing improvement effect rather than a simple increase effect of sangga than the effect of a material consisting of a single component, sapogrylate or bilberry extract.
- the weight ratio of sapogrylate and bilberry extract is less than 1:0.125, it is difficult to expect a synergistic effect as a complex composition because the content of bilberry that can be combined is low compared to the recommended daily amount of sapogrylate 300mg. Even if the weight ratio of the bilberry exceeds 1:8, it is difficult to expect a synergistic effect as a composite composition because the content of sapogrylate complex is low compared to the recommended daily amount of 510 mg of bilberry.
- the bilberry extract used in the present invention is an extract prepared by using bilberry fruit/leaf parts as an extraction solvent, water, C1 to C4 alcohol, or a mixed solvent thereof. Using 5 to 30 times the extraction solvent, extract and concentrate by cold acupuncture method, warm acupuncture method, percoration method, etc. to form soft sea extract, or mix soft sea extract alone or excipients such as soft sea extract and dextran by spray-drying or freeze-drying can be powdered.
- Sapogrylate one of the components of the present invention, is (-)-4-[1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4- As oxobutanoic acid, it has a molecular structure of C 24 H 31 NO 6 and is a drug having the following structure, generally in the form of hydrochloride.
- Sapogrylate which is a component of the present invention, is not limited to hydrochloride, and may include any salt including a free base or hydrochloride.
- the pharmaceutical composition may be to inhibit apoptosis of auditory cells and increase the number of hair cells.
- the complex extract inhibited the apoptosis of auditory cell lines by up to 21.5% at the same concentration compared to the single administration of the bilberry extract, and the number of hair cells in zebrafish was compared with the single administration of sapogrylate. Thus, it was confirmed that the effect was further increased by up to 22%.
- Example 2 in which sapogrylate and bilberry extract are mixed in a weight ratio of 1:3, is 21.6%p, 28.8% higher than that of sapogrylate of 50mpk and 100mpk in click sound condition in the auditory brainstem reaction test for 14 days in mice. p Higher effect, 19.9%p and 24.5%p higher threshold improvement effect than bilberry extract, respectively, were confirmed at the same dose.
- the pharmaceutical composition for the prevention or treatment of hearing loss containing the sapogrylate and bilberry extract as active ingredients is an injection, granule, powder, tablet, pill, capsule, suppository, or gel according to a conventional method.
- any one formulation selected from the group consisting of suspensions, emulsions, drops or liquids may be used.
- the pharmaceutical composition is a suitable carrier, excipient, disintegrant, sweetener, coating agent, swelling agent, lubricant, flavoring agent, antioxidant, buffer, bacteriostatic agent, diluent commonly used in the preparation of pharmaceutical compositions.
- carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, and capsules.
- solid preparations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like in the composition.
- excipients for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like
- lubricants such as magnesium stearate and talc can also be used.
- Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, and the like, and various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents, may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
- Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- As a base material for the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
- the pharmaceutical composition is administered in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, inhalation, topical, rectal, oral, intraocular or intradermal routes. can be administered to the subject.
- the preferred dosage of the composition containing the sapogrylate and bilberry extract as an active ingredient may vary depending on the condition and weight of the subject, the type and extent of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art.
- the daily dose may be 0.01 to 200 mg/kg, specifically 0.1 to 200 mg/kg, and more specifically 0.1 to 100 mg/kg.
- Administration may be administered once a day or may be administered in several divided doses, thereby not limiting the scope of the present invention.
- the 'subject' may be a mammal including a human, but is not limited to these examples.
- the present invention can provide a health food for preventing or improving hearing loss containing sapogrylate and bilberry extract as active ingredients.
- the health food is used together with other foods or food additives other than the sapogrylate and bilberry extract, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be suitably determined according to the intended use thereof, for example, prophylactic, health or therapeutic treatment.
- the effective dose of the compound contained in the health food may be used according to the effective dose of the therapeutic agent, but in the case of long-term intake for health and hygiene or health control, it may be less than or equal to the above range. It is clear that the ingredient can be used in an amount beyond the above range because there is no problem in terms of safety.
- the type of health food is not particularly limited, and examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.
- Bilberry extract was first extracted by adding 100 g of bilberry to 1 L of 90 (v/v)% ethanol aqueous solution and stirring at 40° C. at 1600 rpm for 2 hours. The extract of the first extract was transferred, and 1 L of 70 (v/v)% ethanol aqueous solution was added to the remaining residue, followed by stirring at 40 ° C. at 1600 rpm for 2 hours for second extraction, and then the second extract was transferred. After that, 1L of 70 (v/v)% ethanol aqueous solution was added to the second residue, followed by third extraction in the same manner.
- the alcohol was evaporated while concentrating at a temperature of 50° C. or less.
- the concentrate obtained by the above process was diluted with Brix 1.5 ⁇ 5% and then centrifuged at 6900 rpm for 6 to 12 minutes.
- the supernatant obtained through centrifugation was purified by compression filtration. Thereafter, 1200L of water was added to the purified solution and the first washing was performed for 2 hours. After the second washing was performed by adding 5000L of 70 (v/v)% ethanol to the first washed purified solution, the washing solution was collected and concentrated.
- the concentrate obtained through the above process was spray-dried to prepare an ethanol extract of bilberry in powder form.
- Sapogrylate hydrochloride (manufactured by Pharmacostec) was added to the bilberry ethanol extract in powder form in the weight ratio as shown in Table 1, and the bilberry extract and sapogrylate were added to a mixer and mixed at a speed of 50 rpm for 5 minutes to prepare a composite composition did.
- Example 1 Example 2 Example 3 Example 4 Example 5 Bilberry Ethanol Extract 10g 30g 80g 10g 10g Sappogrylate 10g 10g 10g 30g 80g Composite composition weight 20g 40g 90g 40g 90g
- bilberry 100 g was added to 0.5 L of 70 (v/v)% aqueous ethanol solution and stirred at 60° C. at 1600 rpm for 2 hours for primary extraction.
- the extract of the first extract was transferred, and 0.5 L of 70 (v/v)% ethanol aqueous solution was added to the remaining residue, and the second extract was transferred by stirring at 60 ° C. at 1600 rpm for 2 hours. .
- 0.5 L of 70 (v/v)% ethanol aqueous solution was added to the second residue, followed by third extraction in the same manner.
- the alcohol was evaporated while concentrating at a temperature of 50° C. or less.
- the concentrate obtained by the above process was diluted with Brix 3 ⁇ 5% and then centrifuged at 6900 rpm for 6 to 12 minutes.
- the supernatant obtained through centrifugation was purified by compression filtration. Thereafter, 1200L of water was added to the purified solution and the first washing was performed for 2 hours. After the second washing was performed by adding 5000L of 70 (v/v)% ethanol to the first washed purified solution, the washing solution was collected and concentrated. The obtained concentrate was freeze-dried to prepare an ethanol extract of bilberry in powder form.
- Sapogrylate hydrochloride (manufactured by Pharmacostec) was added to the bilberry ethanol extract in powder form in the weight ratio as shown in Table 2, and the bilberry extract and sapogrylate were added to a mixer and mixed at a speed of 50 rpm for 5 minutes to prepare a composite composition did.
- Example 6 Example 7 Example 8 Example 9 Example 10 Bilberry Ethanol Extract 10g 30g 40g 10g 10g Sappogrylate 10g 10g 10g 20g 50g Composite composition weight 20g 40g 50g 30g 60g
- Bilberry methanol extract was extracted at 28 to 30 °C by immersing 100 g of the pulverized product in 0.5 to 1 L of 70 (v/v)% methanol aqueous solution after pulverizing the frozen bilberry pulp. Thereafter, the supernatant was separated by centrifugation, and citric acid was added to the separated supernatant, and the resulting precipitate was removed and purified. Then, the remaining extract was concentrated, diluted with ethanol, and dried at 60° C. for 36 hours to prepare a dry powder.
- the bilberry methanol extract obtained through the above process was added with sapogrylate hydrochloride (manufactured by Pharmacostec) in the weight ratio as shown in Table 3, and the bilberry extract and sapogrylate were added to a mixer and mixed at a speed of 50 rpm for 5 minutes to obtain a composite composition. was prepared.
- Example 11 Example 12
- Example 13 Bilberry Methanol Extract 10g 30g 50g Sappogrylate 10g 10g 10g Composite composition weight 20g 40g 50g
- 100 g of bilberry was added to 1 L of 70 (v/v)% aqueous methanol solution and stirred at 30° C. at 1600 rpm for 2 hours for primary extraction.
- the extract of the first extract was transferred, and 1 L of a 70 (v/v)% aqueous methanol solution was added to the remaining residue, stirred at 30 ° C. at 1600 rpm for 2 hours, followed by second extraction, and then the second extract was transferred. After that, 1L of 70 (v/v)% aqueous methanol solution was added to the second residue, followed by third extraction in the same manner.
- the alcohol was evaporated while concentrating at a temperature of 50° C. or less.
- the concentrate obtained by the above process was diluted with Brix 3 ⁇ 5% and then centrifuged at 6900 rpm for 6 to 12 minutes.
- the supernatant obtained through centrifugation was purified by compression filtration. Thereafter, 1200L of water was added to the purified solution, and the first washing was performed for 2 hours. After the second washing was performed by adding 5000L of 70 (v/v)% methanol to the first washed purified solution, the washing solution was collected and concentrated. The obtained concentrate was spray-dried to prepare a bilberry methanol extract in powder form.
- sapogrylate hydrochloride manufactured by Pharmacostec
- Example 14 Example 15 Bilberry Methanol Extract 30g 30g Sappogrylate 30g 10g Composite composition weight 60g 40g
- bilberry water extract 30 g of frozen bilberry pulp was placed in 600 mL of water, and hot water extraction was performed at 110 ° C. for 3 hours to obtain a hot water extract, which was concentrated until the solid content became 30% with a vacuum concentrator, and then freeze-dried to prepare a dry powder. .
- Sapogrylate hydrochloride (manufacturer: Pharmacostec) was added to the bilberry extract obtained through the above process in the weight ratio as shown in Table 5, and the bilberry extract and sapogrylate were added to a mixer and mixed at a speed of 50 rpm for 5 minutes to prepare a composite composition did.
- Example 16 Example 17 Example 18 Example 19 Example 20 Bilberry Water Extract 10g 30g 80g 10g 10g Sappogrylate 10g 10g 10g 30g 80g Composite composition weight 20g 40g 90g 40g 90g
- HEI-OC1 House Ear Institute-Organ of Corti 1
- an auditory hair cell derived from the organ of Corti a mouse auditory organ
- FBS fetal bovine serum
- WELGENE Inc. Gyeongsangbuk
- INF- ⁇ 50 U/mL INF- ⁇ (Peprotech Inc., Seoul, Korea)
- DMEM high-glucose Dulbecco's Eagle's medium, Sigma-Aldrich Co., St. Louis, USA
- a noise-induced hearing loss cell line was established by treatment with hydrogen peroxide to generate oxygen species (ROS) caused by oxidative stress that occurs in the process of inducing noise-induced hearing loss.
- ROS oxygen species
- the noise-induced hearing loss-inducing cell line was treated with the complex composition of Example 2 at a concentration of 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 ⁇ g/mL for 1 hour and then treated with 100 ⁇ M hydrogen peroxide for 24 hours, followed by MTT analysis.
- the cytotoxicity and apoptosis effects of hydrogen peroxide were confirmed quantitatively through.
- Example 2 As shown in Table 6 and FIG. 1, the effect of inhibiting auditory cell death in the composite composition of Example 2 was confirmed. It was confirmed that the auditory apoptosis effect was remarkably excellent compared to sapogrylate.
- the EC50 of the composite composition of Example 2 was confirmed to be 0.015 ⁇ g/mL.
- the EC50s of the additionally confirmed sapogrylate and bilberry extracts were 26.43 ⁇ g/mL and 0.16 ⁇ g/mL, respectively, confirming higher efficacy than the single agent.
- Example 2 can exhibit superior apoptosis inhibitory effect than each single agent at a small dose.
- the zebrafish has an inner ear structure similar to that of a human, and it is transparent for easy observation, and the lateral line system, an additional auditory organ, is exposed to the outside. It is used as a model organism for active oxygen-induced hearing loss because it can be observed in
- zebrafish larvae males and females were placed in a tank equipped with a net to separate eggs and adults in a 1:1 ratio, and zebrafish embryos were collected 12 hours later.
- the hydrogen peroxide-induced hearing loss zebrafish model was treated with concentrations of 0.1, 0.5 and 1 ⁇ g/mL from Examples 1 to 5, respectively, and exposed for 12 hours.
- zebrafish fry were anesthetized with 0.02% tricaine, and auditory hair cells were stained with 0.1% YO-PRO for 30 min. After observation, counting.
- Example 2 when the complex composition of Example 2 was administered at 0.1 ⁇ g/mL, an average of 12.74 most hair cells could be identified, which was obtained in Example 2 through comparison of the threshold improvement effects of each bilberry extract and sapogrylate. It was confirmed that the hair cell protection efficacy of the complex composition of
- mice The animals used in the experiment were bred at a temperature controlled at 25 ⁇ 2°C in an environment with lights turned on at intervals of 12 hours. Loss) model mice were prepared.
- the hearing threshold was measured using the Auditory Brainstem Response (ABR) measurement method.
- ABR Auditory Brainstem Response
- the sample was orally administered at the same time every day to the complex composition treatment group of Example 2 from 20 hours after exposure to noise, and the control group did not administer the sample. All mice were measured after confirming the state of the ear canal through an otoscope before the experiment.
- the click sound (wide frequency) was evaluated by gradually lowering the sound by 5 dB from 80 dB.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | |
빌베리 에탄올 추출물 | 10g | 30g | 80g | 10g | 10g |
사포그릴레이트 | 10g | 10g | 10g | 30g | 80g |
복합조성물 무게 | 20g | 40g | 90g | 40g | 90g |
실시예 6 | 실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 | |
빌베리 에탄올 추출물 | 10g | 30g | 40g | 10g | 10g |
사포그릴레이트 | 10g | 10g | 10g | 20g | 50g |
복합조성물 무게 | 20g | 40g | 50g | 30g | 60g |
실시예 11 | 실시예 12 | 실시예 13 | |
빌베리 메탄올 추출물 | 10g | 30g | 50g |
사포그릴레이트 | 10g | 10g | 10g |
복합조성물 무게 | 20g | 40g | 50g |
실시예 14 | 실시예 15 | |
빌베리 메탄올 추출물 | 30g | 30g |
사포그릴레이트 | 30g | 10g |
복합조성물 무게 | 60g | 40g |
실시예 16 | 실시예 17 | 실시예 18 | 실시예 19 | 실시예 20 | |
빌베리 물 추출물 | 10g | 30g | 80g | 10g | 10g |
사포그릴레이트 | 10g | 10g | 10g | 30g | 80g |
복합조성물 무게 | 20g | 40g | 90g | 40g | 90g |
μg/mL | CTL | H2O2 | 0.001 | 0.005 | 0.01 | 0.05 | 0.1 | 0.2 |
상대적 세포 생존율 |
100 | 0.0 | 53.7 | 60.7 | 77.1 | 89.9 | 97.3 | 93.7 |
Claims (6)
- 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 빌베리 추출물은 정제수, C1 ~ C4의 알콜 또는 이들의 복합용매로 추출하여 얻어진 것을 특징으로 하는 난청 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 난청은 소음성 난청, 이독성 난청, 노인성 난청 및 돌발성 난청으로 이루어진 군에서 선택된 것을 특징으로 하는 난청 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 약학조성물은 사포그릴레이트 및 빌베리 추출물이 1:(0.125~8)의 중량비로 포함되는 것을 특징으로 하는 난청 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 약학조성물은 청각세포의 세포사멸을 억제하고 유모세포 수를 증가시키는 것을 특징으로 하는 난청 예방 또는 치료용 약학조성물.
- 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 개선용 건강식품.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280023002.5A CN117042762A (zh) | 2021-03-26 | 2022-03-11 | 包含沙格雷酯和欧洲越桔提取物作为活性成分的用于预防或治疗听力损失的复合组合物 |
US18/282,790 US20240173372A1 (en) | 2021-03-26 | 2022-03-11 | Complex composition for preventing or treating hearing loss including sarpogrelate and vaccinium myrtillus extract as active ingredients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0039541 | 2021-03-26 | ||
KR1020210039541A KR102323400B1 (ko) | 2021-03-26 | 2021-03-26 | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022203251A1 true WO2022203251A1 (ko) | 2022-09-29 |
Family
ID=78610129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003423 WO2022203251A1 (ko) | 2021-03-26 | 2022-03-11 | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240173372A1 (ko) |
KR (1) | KR102323400B1 (ko) |
CN (1) | CN117042762A (ko) |
WO (1) | WO2022203251A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102323400B1 (ko) * | 2021-03-26 | 2021-11-09 | (주)아이엠디팜 | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037738A (ja) * | 2009-08-08 | 2011-02-24 | Chube Univ | 難聴又は耳鳴りの予防・治療剤 |
KR101905865B1 (ko) * | 2017-04-11 | 2018-10-08 | 아주대학교산학협력단 | 사포그릴레이트를 유효성분으로 포함하는 감각신경성 난청의 예방 또는 치료용 조성물 |
KR102175201B1 (ko) * | 2019-09-06 | 2020-11-06 | (주)아이엠디팜 | 빌베리 추출물을 유효성분으로 함유하는 감각신경성 난청 예방 또는 치료용 조성물 |
KR102323400B1 (ko) * | 2021-03-26 | 2021-11-09 | (주)아이엠디팜 | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180089207A (ko) | 2017-01-31 | 2018-08-08 | 동국제약 주식회사 | 해조류 대황 추출물을 유효성분으로 함유하는 감각신경성 난청의 예방 또는 치료용 약학적 조성물 또는 건강기능식품 |
-
2021
- 2021-03-26 KR KR1020210039541A patent/KR102323400B1/ko active IP Right Grant
-
2022
- 2022-03-11 WO PCT/KR2022/003423 patent/WO2022203251A1/ko active Application Filing
- 2022-03-11 US US18/282,790 patent/US20240173372A1/en active Pending
- 2022-03-11 CN CN202280023002.5A patent/CN117042762A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011037738A (ja) * | 2009-08-08 | 2011-02-24 | Chube Univ | 難聴又は耳鳴りの予防・治療剤 |
KR101905865B1 (ko) * | 2017-04-11 | 2018-10-08 | 아주대학교산학협력단 | 사포그릴레이트를 유효성분으로 포함하는 감각신경성 난청의 예방 또는 치료용 조성물 |
KR102175201B1 (ko) * | 2019-09-06 | 2020-11-06 | (주)아이엠디팜 | 빌베리 추출물을 유효성분으로 함유하는 감각신경성 난청 예방 또는 치료용 조성물 |
KR102323400B1 (ko) * | 2021-03-26 | 2021-11-09 | (주)아이엠디팜 | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 |
Non-Patent Citations (2)
Title |
---|
CHANG GUN CHO, CHI JUN HYUK, SONG JAE-JUN, LEE EUN KYEONG, KIM BO HAE: "Evaluation of Anxiety and Depressive Levels in Tinnitus Patients", KOREAN JOURNAL OF AUDIOLOGY, vol. 17, no. 2, 1 January 2013 (2013-01-01), pages 83 - 89, XP055640579, ISSN: 2092-9862, DOI: 10.7874/kja.2013.17.2.83 * |
KAPUSUZ ZELIHA; ÖZKIRIş MAHMUT; KALA MEHTAP; SAYDAM LEV: "Protective Role of Bilberry Extract Against Cisplatin Induced Ototoxicity in Rats", INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, SPRINGER INDIA, INDIA, vol. 65, no. 4, 20 March 2013 (2013-03-20), India , pages 339 - 344, XP035359530, ISSN: 2231-3796, DOI: 10.1007/s12070-013-0642-x * |
Also Published As
Publication number | Publication date |
---|---|
KR102323400B1 (ko) | 2021-11-09 |
CN117042762A (zh) | 2023-11-10 |
US20240173372A1 (en) | 2024-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018117659A1 (ko) | 청대 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물 | |
WO2022203251A1 (ko) | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 | |
WO2018236011A1 (ko) | 죽순 효소분해물 또는 죽순 발효물을 유효성분으로 포함하는 장기능 저하 예방, 개선 또는 치료용 조성물 | |
WO2020149636A1 (ko) | 아우쿠빈을 포함하는 안구 건조증의 예방 또는 치료용 약학적 조성물 | |
WO2017183902A1 (ko) | 인진, 지유 및 울금 추출물 및 항바이러스제를 유효성분으로 포함하는 간질환 예방 또는 치료용 조성물 | |
WO2016186349A2 (ko) | 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물 | |
WO2012121560A2 (ko) | 난청의 예방 또는 치료용 조성물 | |
WO2019050123A1 (ko) | 가자나무열매추출물 및 암라추출물을 포함하는 비만 또는 고지혈증 개선용 식품 조성물 | |
WO2019004610A1 (ko) | 적포도잎 추출물을 유효성분으로 함유하는 난청의 예방 또는 치료용 조성물 | |
KR100817600B1 (ko) | 갈근추출물을 함유하는 약학조성물 | |
WO2020085799A1 (ko) | 도라지 사포닌을 포함하는 표준화된 도라지 추출물 또는 막분리 도라지 사포닌 추출물을 함유하는 간질환의 예방 또는 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 | |
WO2021045569A1 (ko) | 빌베리 추출물을 유효성분으로 함유하는 감각신경성 난청 예방 또는 치료용 조성물 | |
WO2018190608A1 (ko) | 사포그릴레이트를 유효성분으로 포함하는 감각신경성 난청의 예방 또는 치료용 조성물 | |
WO2018230942A1 (ko) | 호장근 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 및 치료용 조성물 | |
WO2021080298A1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
US20200061142A1 (en) | Composition for preventing or treating gastritis or peptic ulcer | |
WO2018052171A1 (ko) | 율무 추출물을 포함하는 위암 치료용 조성물과 그 추출방법 | |
WO2020263010A1 (ko) | 안토시아닌-음전하성 다당류 복합체를 유효성분으로 포함하는 위염 또는 소화성 궤양 예방, 개선 또는 치료용 조성물 | |
WO2020166962A2 (ko) | 적포도잎 추출물을 유효성분으로 함유하는 이명의 예방 또는 치료용 조성물 | |
WO2019103248A1 (ko) | 섬바디 추출물을 포함하는 동맥경화증의 예방 또는 치료용 조성물 | |
KR20230063343A (ko) | 사포그릴레이트 및 빌베리 추출물을 유효성분으로 함유하는 난청 예방 또는 치료용 복합조성물 | |
WO2019225845A1 (ko) | 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물 | |
WO2014126269A1 (ko) | 남성 성기능 개선 및 불임 치료용 약학적 조성물 | |
WO2024117389A1 (ko) | 치매 예방 또는 개선용 조성물 및 그 제조방법 | |
WO2024096280A1 (ko) | 포도나무 줄기 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 알츠하이머 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22775953 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18282790 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280023002.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22775953 Country of ref document: EP Kind code of ref document: A1 |